Fennec Pharmaceuticals, Inc. (ADH) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a biopharmaceutical company founded in 1996 and headquartered in Research Triangle Park, North Carolina. Originally incorporated as Adherex Technologies Inc., the company changed its name to Fennec Pharmaceuticals in September 2014 to reflect its focused mission on pediatric oncology. The company went public in September 2017 and has since established itself as a specialized player in the rare disease pharmaceutical space, specifically targeting the prevention of chemotherapy-induced hearing loss in cancer patients.

Ask drillr about Fennec Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

59.22M

Net Income (TTM)

−3.25M

Op. CF (TTM)

−2.04M

Latest newsMore news →

Adherex Technologies, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period.40d ago

Latest newsMore news →

Fennec Pharmaceuticals announced an oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical study of Pedmark in Japan at SIOP 2026, with the primary endpoint met as ASHA-defined hearing loss occurred in 24.0% of patients versus the prespecified historical benchmark of 56.4% (P=0.001).3d ago Adherex Technologies, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period.40d ago